Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) reached a new 52-week low during trading on Thursday . The company traded as low as $8.30 and last traded at $8.38, with a volume of 49,268 shares traded. The stock had previously closed at $8.68.

A number of research firms have recently commented on OXFD. Piper Jaffray Cos. reissued a “buy” rating on shares of Oxford Immunotec Global PLC in a research note on Sunday, June 26th. BTIG Research reissued a “buy” rating and set a $17.00 target price on shares of Oxford Immunotec Global PLC in a research note on Monday, June 27th. Finally, Zacks Investment Research cut shares of Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a research note on Wednesday, July 6th.

The firm’s market cap is $186.17 million. The firm has a 50-day moving average price of $8.90 and a 200-day moving average price of $9.88.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.32) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.32). The business had revenue of $17.10 million for the quarter, compared to analyst estimates of $16.96 million. During the same quarter in the prior year, the company earned ($0.31) EPS. The firm’s revenue for the quarter was up 23.9% on a year-over-year basis. Equities research analysts anticipate that Oxford Immunotec Global PLC will post ($1.28) EPS for the current fiscal year.

An institutional investor recently raised its position in Oxford Immunotec Global PLC stock. OppenheimerFunds Inc. raised its position in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 0.5% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,068,967 shares of the company’s stock after buying an additional 5,440 shares during the period. OppenheimerFunds Inc. owned approximately 4.74% of Oxford Immunotec Global PLC worth $12,293,000 at the end of the most recent quarter.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.